Glucocorticoid Therapy and Miglitol Ameliorate Reactive Hypoglycemia Secondary to Late Dumping Syndrome.

Intern MedFeb 24, 2026 (epub)

Manabu Saito, Hiroshi Uchino, Arisa Yoshida et al.

✦ AI-curated · Sources linked

Case in brief

A 73-year-old man developed symptomatic reactive hypoglycemia attributed to late dumping syndrome after esophagectomy with gastric tube reconstruction. Frequent dietary management and voglibose, a non-absorbable α-glucosidase inhibitor, did not control the hypoglycemia. After treatment was changed to low-dose prednisolone and miglitol, an absorbable α-glucosidase inhibitor, the hypoglycemia improved and his symptoms resolved.

What made this case unusual

Hypoglycemia persisted despite dietary management and voglibose, but improved after switching to low-dose prednisolone and miglitol.

Diagnostic / clinical pearl

In this reported case, late dumping syndrome caused reactive hypoglycemia after esophagectomy; persistent symptoms despite dietary measures and voglibose improved with low-dose prednisolone and miglitol.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.